Disc Medicine UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. I guess we will get started. Thank you. Thank you for joining our inaugural UBS Global Biopharma Conference 2026. My name is Joon Lee, one of the biotech analysts at UBS. For this session, we have John Quisel, CEO of Disc Medicine. John, thank you so much for spending your time with us. For the audience who may be new to the story, could you just give a quick intro about your company, yourself, and why investors should be paying attention to Disc Medicine?
Yeah, thank you. It is great to be here. Disc Medicine, we have been public for about four years, and we focus on manipulating metabolic pathways in red blood cells and erythrocytes to address a wide range of hematologic disorders that arise in the red blood cell compartment. We have three clinical stage programs, all focusing on controlling either heme or iron metabolism, again, to address diseases that arise in the red blood cells. Our lead program just had a prominent phase III readout, successful, excellent readout across all the endpoints in a rare disease called erythropoietic protoporphyria. Then we have two pipeline programs that are in phase II, proof of concept achieved, progressing towards phase III, and they are in the myeloproliferative disease space.
Congrats on all the success. Let us start from the basic. Tell us a little bit about EPP and XLP and what the unmet needs are and how bito could fill that unmet need based on the data that you have.
Sure. These are porphyrias, erythropoietic protoporphyria, EPP, and then a closely related disease, different genotype, but same phenotype called XLP or X-linked protoporphyria. These are both diseases that are caused by genetic mutations in enzymes of the heme biosynthetic pathway. When those enzymes are deficient, you get a buildup of metabolites that are produced in the process of heme biosynthesis, which many people do not realize, this is one of the single most active biosynthetic pathways in the human body because there is a tremendous amount of red blood cell production happening all the time. Every red blood cell has a tremendous amount of heme in it. So it is this high velocity, high volume pathway, and when it is broken genetically, you get these metabolites that just spew out of the red blood cells and create toxic side effects. In this case, the key metabolite is called protoporphyrin IX.
It's the last metabolite of the pathway, and this metabolite does two things that are quite damaging to the body. In the first instance, it absorbs light energy, and so when a patient whose blood is full of this chemical goes out into the sunlight, that sunlight activates the protoporphyrin IX, which becomes a free radical and essentially starts to burn the patient from the inside of the bloodstream. It's excruciatingly painful. These pain attacks are reported as being like having lava flowing through the blood, and takes days for these pain attacks to resolve. Needless to say, after a few of these attacks, patients essentially retreat into the darkness and choose their entire career, hobbies, et cetera, built around being in the dark.
A life-changing and profound disease. The second thing that the protoporphyrin IX does is it accumulates in the hepatobiliary system, causing backing up and leading to liver damage. The liver in these patients can turn purple- with the buildup of protoporphyrin IX.
While about a third of patients will have some evidence of liver damage- 2%-5% will go into overt liver failure, obviously a very serious consequence of the disease.
There is a drug approved for the hepatic porphyria.
There is, that's right. Well, that's a different disease.
a different kind of phenotype, but it's another mutation in the heme biosynthetic pathway that leads to a different toxin building up in the body. You're correct, because there, the target organ is the liver.
siRNA from Alnylam, called GIVLAARI, has been effective in the hepatic porphyria space.
Sounds like a horrible disease, and you hit all endpoints on phase III APOLLO this time. It will be a resubmission. What made this work, this trial work, as opposed to prior trial, which missed the endpoint?
Yeah. So we had a phase II program, as you say. We were in the process of getting accelerated approval.
before things went sideways in a fairly dramatic way. But actually, the primary endpoint hit, and if you look at the active arm in phase II, the results were amazing. Patients were spending more time in light. They were having close to 75% fewer pain attacks.
They reported, I think all but one patient reported feeling much better on therapy. Many of those endpoints were nominally stat sig. What made it challenging is that in the first secondary endpoint, the placebo group outperformed and destroyed the stat sig, but there was not power for that endpoint in phase II. There, the powering was around measuring the toxic metabolite, which we clearly decreased, that was stat sig. So we hit our primary in the phase II program, and that is what led to the possibility of an accelerated approval.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
